Published January 2013 | 18 Pages | 29 Exhibits |
All companies include technology, market(s), key executive, and contact information.
Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies
This report is included in LSI's Emerging Medical Technologies® Database.
•A crystal form of zirconium silicate designed to treat patients with kidney and liver disease
•A non-invasive, low-cost, wireless, cloud-leveraged technology to accurately diagnose functional gastrointestinal (GI) disorders
•A patient transport system that is independent of a magnet vendor and can move a fully anesthetized patient between adjacent rooms for surgery and imaging
•A portable and disposable suit for treating hypothermia that can draw heat off of the body in a much more rapid process than either gel pads or cooling blankets
•A simple and robust lab-on-a-chip capable of performing hundreds of distinct parallel assays over a small surface area, with minimal patient sample and without compromising performance
•An economical, programmable, advanced therapeutic bed system to treat pressure ulcers, accelerate healing, and improve patient comfort
•Bio-production of chemical molecules using micro-algae to mass produce lipids, pharmaceuticals, and cosmetics, among other non-medical applications
•Cutting-edge computational technologies to identify drug candidates against previously inaccessible biological targets
•Dental implants consisting of a titanium threaded rod that is treated in a way (at the molecular level), whereby bone grows into the titanium, allowing the rod to provide a highly secure base, and eliminating the potential for bone deterioration that occurs when partials or bridges are placed in the mouth
•Extremely compact system for real-time direct cochlear nerve monitoring during skull base surgeries
•Genetic tools to develop more precise, non-invasive tests for cancer and hard-to-diagnose forms of Down syndrome and markers for autism
•Handheld, compact, and portable gamma camera systems that can be used with existing MRI systems or on their own
•Human induced pluripotent stem cell (iPSC) lines and tissue cells for in vitro drug development, in vivo cellular therapeutics, and stem cell banking
•In vitro diagnostic test to diagnose coronary heart disease in asymptomatic individuals and to predict pathological events in patients with existing cardiovascular disease
•Insoles equipped with advanced pressure sensors that will empower diabetics to play a more active role in the prevention of foot complications such as ulcers and amputation
•Micro sensors mounted on fibre optics for diagnostic uses in dentistry, urinalysis, blood analysis, glucose testing, and coronary artery disease (CAD)
•New class of antibiotics that are active against drug-resistant bacteria
•Next-generation software solution that provides more accurate contouring of lesions and organs than any current competitive method
•Non-surgical, injectable products for: 1-selective, non-ablative, local fat reduction and 2-the treatment of symptomatic exophthalmos
•Novel drugs and molecular diagnostic products to target cancer, central nervous system (CNS), and infectious diseases
•Pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications
•Plant-based manufacturing platform for ultra-low-cost monoclonal antibodies, protein drugs, and vaccines with applications for human immunodeficiency virus (HIV) and cancer - for as little as one-tenth of the manufacturing cost of other biopharmaceutical production systems
•Quantitative, objective molecular tests to help enable more effective management of patients with autoimmune and inflammatory diseases, such as rheumatoid arthritis (RA)
•Second-generation nitroxyl (HNO) chemistry platform to develop drugs for the treatment of acute and chronic heart failure
•Technology to isolate personalized human cells from skin, human airways, and the gastrointestinal tract using minimally-invasive approaches and non-embryonic sources
•Technology to kill the deadly superbug Methicillin Resistant Staphylococcus Aureus (MRSA) in homes and healthcare facilities
•The first and only once-yearly, injection-free, GLP-1 therapy for the treatment of type 2 diabetes
•The only suture like mesh fixation device that enables durable and easy fixation of soft tissue prosthetics (including hernia mesh products) for a variety of procedures
•Third-generation, fully-synthetic bone graft substitute that is not pharmacological in nature and does not contain any human or animal derived components
We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
